# A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT01585233** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** ASKP1240
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01585233
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-30
- **Primary completion:** 2014-06-30
- **Final completion:** 2015-01-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01585233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01585233, "A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01585233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*